What does PT-141 make you feel like?

The only controlled reports come from clinical trials of bremelanotide, the approved drug. The most common effects were nausea, flushing and headache, with nausea in about 40% of women in the phase 3 trials, most often after the first dose. Injection site reactions were reported in about 13%. About 1% developed darkening of the gums or skin, a sign of melanocortin activity, and blood pressure rose briefly after each dose.

On desire itself, the trials measured modest changes on questionnaires rather than strong subjective effects, and personal accounts online aren’t controlled data. Research-grade PT-141 isn’t for human use. Labs studying reproductive signaling can also compare Kisspeptin-10. Every lot is tested, with reports in our COA library. Shop PT 141.